Bob Duggan, Summit CEO (via Summit Investments)
December 21, 2021 11:25 AM ESTUpdated 12:16 PM
R&D

Bil­lion­aire Bob Dug­gan's new an­tibi­ot­ic play fails a Phase III tri­al, and in­vestors aren't hap­py

Nicole DeFeudis

Editor

Bob Dug­gan — the bil­lion­aire in­vestor fa­mous for turn­ing Phar­ma­cyclics from a pen­ny stock to a $20 bil­lion com­pa­ny — placed a hand­some bet on the com­pa­ny …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times